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SYNOPSIS 
Outcomes were analyzed for patients treated for low-grade appendiceal mucinous 
neoplasms (LAMN) with remote mucinous peritoneal deposits (MPD). Patients with acellular 
remote MPD had better outcomes on average than patients with cellular MPD. Approaches 
such as active surveillance may have a role in selected patients with LAMN and AMPD. 
 
 
ABSTRACT 
Background:  Occasionally, low-grade appendiceal mucinous neoplasms (LAMN) present 
with mucinous peritoneal deposits (MPD) localized to periappendiceal tissue or diffused 
throughout the peritoneum. This study was aimed at evaluating the relevance of mucin 
cellularity for predicting outcomes of LAMN with remote MPD. 
Methods: The records of patients with LAMN and remote MPD who underwent initial 
assessment at a comprehensive cancer center in 1990–2015 were reviewed, and diagnostic 
procedures, treatments, and outcomes were analyzed. 
Results: Of 48 patients included in the analysis, 19 had cellular MPD (CMPD) and 29 had 
acellular MPD. Of 33 patients who underwent cytoreductive surgery, 30 had a complete 
cytoreduction. The three patients with an incomplete cytoreduction had CMPD. In follow-up 
(median, 4 years), six patients died of the disease. All six had CMPD. Of 11 patients who 
had progression of disease, 10 had CMPD.   
Conclusion: Cellularity of remote MPD is an important determinant of disease outcome in 
LAMN. Approaches such as active surveillance may have a role in selected patients with 
LAMN and AMPD.  
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Mucinous appendiceal neoplasms represent one-third of epithelial appendiceal tumors, 
forming a heterogeneous group.1,2  Although low-grade appendiceal mucinous neoplasms 
(LAMN) are considered slow growing and indolent, a proportion of them present with 
mucinous peritoneal deposits. These deposits may be localized to periappendiceal tissue or 
diffusely spread throughout the peritoneal cavity (LAMN with remote mucinous peritoneal 
deposits [MPD]). LAMN with remote MPD follow an indolent but variable disease course with 
a poorly defined mortality; overall survival at 10 years ranges from 46 to 63%.1,3  Currently, 
cytoreductive surgery (CRS), or tumor debulking, with or without intraperitoneal 
chemotherapy is the most common treatment strategy for metastatic appendix tumors 
regardless of cellularity of mucin.4,5 Such an approach may reduce recurrence and 
progression to the clinical syndrome of pseudomyxoma peritonei, characterized by the 
massive accumulation of mucin within the peritoneal cavity.6,7  However, in view of biological 
heterogeneity and variable outcomes, such aggressive treatment may not be necessary in 
all patients.  
 
Few studies to date have focused on reporting outcomes for LAMN with MPD in relation to 
cellularity of mucin. Cellularity of peritoneal mucin is one of the features thought to provide 
prognostic information. MPD can be cellular (containing epithelial components) or acellular 
(completely devoid of cells). Several studies have reported better outcomes in patients with 
acellular MPD (AMPD) than in patients with cellular MPD (CMPD).6,8-10  Yantiss et al. 
published the first study reporting on cellularity of mucin within the right lower quadrant.  In 
their multi-center study, they examined the prognostic significance of LAMN with mucin 
localized to the periappendiceal tissue. Seven of 65 patients developed diffuse mucinous 
ascites following complete macroscopic resection: 5 (33%) of 15 patients with cellular mucin 
and 2 (4%) of 50 patients with acellular mucin.11 There was one death from disease in the 
cellular-mucin group and no deaths in the acellular-mucin group.   
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It is unclear whether LAMN with MPD remote from the appendix or right lower quadrant 
behave similarly. Although previous studies have not specifically addressed the prognostic 
value of cellularity of MPD beyond the right lower quadrant, among three series of LAMN 
patients with remote MPD a single recurrence was reported among 15 patients with AMPD 
(see Supplementary Table 1).8-10 
 
Recent AJCC classifications have sought to address the apparent prognostic difference 
between acellular and cellular MPD, with a new subclassification for disease outside the 
right lower quadrant.  Based on results of previous studies8,9,10 demonstrating improved 
outcome in patients with AMPD in addition to the observation that disease recurs in a small 
subset of patients, LAMN with   AMPD is now classified as M1a and LAMN with CMPD is 
classified as M1b in the 8th edition of the AJCC staging manual.12 However, given the paucity 
of data in this area, further studies are necessary to support this new subclassification. 
 
The aim of the present study was to compare the rates of peritoneal recurrence and 
progression to the syndrome of pseudomyxoma peritonei between patients with AMPD and 
patients with CMPD remote from the right lower quadrant. Our hypothesis, based on the 
above findings, was that the risk of disease progression is lower in patients with remote 
AMPD than in patients with CMPD. If this hypothesis is correct, it may be appropriate to 
consider less radical interventions for patients with remote AMPD, similar to patients with 
LAMN and localized periappendiceal mucin, who are typically observed in the absence of 
progression of disease.  
 
METHODS 
We included patients older than 18 years with a diagnosis of LAMN with MPD remote from 
the appendix who were assessed at Memorial Sloan Kettering Cancer Center (MSK) 
between 1990 and 2015. LAMN patients with localized periappendiceal mucin on 
presentation (mucin involving only the serosa of the right ovary, terminal ileum, 
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mesoappendix, or cecum) were excluded. The study was approved by MSK’s Institutional 
Review Board.   
 
We searched the MSK pathology database, Darwin, using the keywords mucin and 
pseudomyxoma peritonei. This initial search yielded >3000 potential cases, which were 
reviewed to determine suitability for inclusion. In cases deemed appropriate for inclusion, 
electronic medical records were reviewed, and data were collected on age at diagnosis, sex, 
and date of initial diagnosis. In addition, we collected data on the index diagnostic procedure 
and MPD sampling based on the magnitude of operation and volume of sampling: (i) biopsy 
alone, (ii) appendectomy with or without a salpingo-oophorectomy, and (iii) CRS, including 
segmental colectomy. In patients who underwent a biopsy or appendectomy/salpingo-
oophorectomy, the sampling of mucin varied and, unlike in CRS patients, did not involve 
removal of all visible disease. Data on treatment and outcomes including disease recurrence 
and patient deaths were also collected.  
 
There is no International Classification of Diseases code for LAMN that indicates degree of 
cellularity of peritoneal deposits. The determination of CMPD or AMPD was therefore based 
on review of pathology reports issued by specialized pathologists at the time of tissue 
acquisition. All patients were considered to have macroscopic remote MPD at the time of 
initial sampling. The index sampling method of the MPD was variable and ranged from 
potentially nonrepresentative diagnostic biopsies to localized resection or more extensive 
CRS. Where clarification on the pathology reporting or terminology used was required, a 
pathology review was performed by an expert pathologist (J.S.). Mucin-specific terms and 
phrases identified in the pathology reports that were deemed to indicate AMPD included 
“acellular,” “devoid of cells,” and “no epithelium seen.” Mucin-specific terms and phrases that 
were deemed to indicate CMPD included “cellular,” “scant cellularity,” “containing 
epithelium,” and “adenomucinosis.” Histological examples of CMPD and AMPD are shown in 
Fig. 1.  All tumors were classified as low grade, or well differentiated (G1) according to the 
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8th edition of the AJCC staging manual.12 These tumors lack invasive features and contain 
tall columnar cells with low-grade cytologic atypia without signet ring cells. Signet ring 
features were not present in any of the cellular deposits. 
 
At the index assessment at MSK, patients underwent a CT scan of the abdomen and pelvis, 
and data were collected on whether the patient had visible peritoneal disease at initial 
operative assessment. We then reviewed the initial recommendation made by the consulting 
MSK surgical or medical oncologist, which was typically confirmed at a multidisciplinary 
conference. These initial treatment recommendations were grouped into two categories: 
observe the patient or perform CRS within 6 months of initial diagnosis. Data on the 
completeness of cytoreduction for patients who underwent CRS were recorded as 
Sugarbaker cytoreduction completeness scores.13 Any subsequent surgical procedures were 
also recorded.   
 
Patients were followed up with regular clinical examination in addition to at least annual CT 
scans. Survival and recurrence data were based on the information obtained during follow-
up. The date of death or last known follow-up was used to estimate survival. The first date of 
progression or recurrence documented on a CT report or in clinical notes was recorded as 
the date of recurrence. Patients with inadequate follow-up (≤12 months) were excluded from 
the analysis. Statistical analysis of overall, progression-free, and recurrence-free survival 
was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL) and the Kaplan-Meier 
method for constructing survival curves. Subgroups were compared by the log-rank test, 
with statistical significance defined as P < 0.05. 
 
 
RESULTS 
Between 1990 and 2015, 71 patients with a diagnosis of LAMN with remote MPD were seen 
for an initial assessment at MSK. Twenty-three of those patients were excluded because 
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they were seen for a second opinion or a pathology review alone or they did not have more 
than 12 months of follow-up. The patients’ baseline clinical and pathological characteristics 
and recommended treatments are listed in Table 1.  
 
Four patients had undergone CRS without intraperitoneal chemotherapy prior to initial 
evaluation at MSK: two within 12 months of presentation at MSK and two >12 months earlier 
(range, 3–37 months). At initial assessment at MSK, a diagnosis of LAMN with either CMPD 
(19 patients, 40%) or AMPD (29 patients, 60%; Supplementary Fig. 1) was made based on 
pathology findings. CT identified visible disease in 33 patients (69%): 15/29 with AMPD and 
18/19 with CMPD (Fig. 2).  
 
The initial treatment recommendation at MSK was CRS within 6 months for 40 patients and 
observation for 8 patients. Of the 8 patients who were recommended initial observation at 
MSK, sampling of MPD was performed as part of a biopsy in 1 patient, 
appendectomy/salpingo-oophorectomy in 3 patients, and CRS at other institutions in 4 
patients.  None of the patients in the observation group had demonstrable abdominal 
disease on CT scan. Two of the 40 CRS patients pursued treatment at other institutions, and 
38 underwent surgery at MSK with a plan for complete cytoreduction.  At laparoscopy, 2 of 
the 38 patients had no visible or pathological (frozen section) evidence of disease, and 
therefore CRS was not performed. In three other patients, CRS was not attempted due to 
the presence of extensive disease. Complete CRS to no gross residual disease was 
achieved in 30 (91%) of the remaining 33 patients. The three patients in whom complete 
CRS was not achieved (cytoreduction completeness score 2 [moderate residual disease]) 
had CMPD on initial sampling. In 27 patients, intraperitoneal chemotherapy was used as an 
adjunct to CRS.  Of the 29 patients with AMPD, 25 were recommended to undergo CRS. 
Five patients were upstaged from AMPD to CMPD after CRS. Two of the five patients had 
index sampling with biopsy alone; four of the five had visible disease on baseline CT. 
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As almost half of the patients were initially seen at MSK in 2010–2015, the median follow-up 
for the 40 survivors was 4 years (min-max, 1-17 years). Of the eight patients who died, six 
died of disease; all six had CMPD. Following initial management at MSK, 11 of the total 48 
patients had progression of disease during the follow-up period: 10 of the 19 patients in the 
CMPD group and 1 of the 29 patients in the AMPD group (Table 2). Of the 38 patients who 
underwent CRS at MSK within 6 months after initial assessment, 9 had subsequent 
progression of disease. The Kaplan-Meier curves for disease-specific survival (P = 0.03) and 
progression-free survival (P < 0.001) were well stratified by cellularity of MPD (Fig. 3 and 
Supplementary Fig. 2). The single patient with remote AMPD who had progression 6 years 
after diagnosis was initially observed after appendectomy. CRS was recommended at the 
time of progression but was postponed due to medical comorbidities, and the patient 
ultimately pursued treatment elsewhere with no further follow-up available.   
 
The actuarial progression-free survival rates at 1, 3, and 5 years were 77%, 64%, and 46% 
for patients with CMPD (including patients upstaged to CMPD after debulking; n = 24) in 
comparison to 100% at 5 years in the APMD group (n = 24). The actuarial overall survival 
rates at 1, 3, and 5 years were 100%, 88%, and 88% for the CMPD group in comparison to 
100% at 3 years and 91% at 5 years in the AMPD group. Of note, within the small subset of 
4 patients who did not undergo CRS (Supplementary Fig. 1), no disease progression was 
reported with median follow-up of 44 months (range 36-70 months).   
 
Of the 19 patients with CMPD, 10 had a baseline peritoneal cancer index (PCI) score > 20. 
Five of those patients developed recurrent disease, and three died of disease. Of the 29 
patients with AMPD, 2 had a baseline PCI score > 20. Neither of the two patients had a 
recurrence after cytoreduction. 
 
Of the 38 CRS patients, 5 subsequently underwent additional abdominal surgery. One of the 
five patients underwent resection of a pulmonary recurrence. That patient had CMPD. The 
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remaining four patients had AMPD. One of the four patients underwent a right colectomy 
due to the presence of an incidental 2-cm carcinoid in the CRS appendix specimen, another 
patient underwent incisional hernia repair, and two others underwent procedures (right 
colectomy and resection of an adnexal lesion) for unrelated abdominal abnormalities 
detected incidentally on follow-up imaging.  
  
 
 
 
DISCUSSION 
This study differs from previously published studies in that it focused specifically on LAMN 
with AMPD remote from the right lower quadrant.  Our findings indicate that LAMN patients 
with remote AMPD have longer progression-free survival and longer overall survival on 
average than LAMN patients with CMPD. In the 29 LAMN patients with remote AMPD in our 
study, the risk of disease recurrence or progression after initial diagnosis was 3.4%. The 
better outcomes in AMPD patients cannot be attributed to treatment alone and likely reflect 
an indolent biology. 
 
Of the total 20 LAMN patients with remote AMPD in four previous studies,8-10,14 only 1 
experienced disease progression.10 Thus, for the combined 49 patients (including 29 from 
our study), the rate of disease recurrence was 4%. It is not possible to determine whether 
initial management influenced outcomes, due to unmeasurable selection bias. However, the 
proportion of patients who were initially managed by observation in the four previous studies 
appears to range from 20 to 39%. The two patients with remote AMPD who experienced 
progression were initially managed by appendectomy and initial observation (rather than 
CRS). They experienced progression more than 5 years after initial diagnosis.  
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The results of these studies are similar to those reported by Yantiss et al., in which LAMN 
patients with pariappendiceal AMPD had a low rate of recurrence (2/50).11 Similarly, Pai et 
al.8 reported outcomes for 116 patients with appendiceal mucinous neoplasms over a 30-
year period, including 17 patients with LAMN and copious extra-appendiceal mucin, defined 
by the authors as mucin visualized on gross inspection. For this group, outcomes were 
reported for 14 patients with a mean follow-up of 84 months. One of the 14 patients had a 
recurrence. Of the patients with mucin outside the right lower quadrant, long-term outcome 
was available for two patients, neither of whom had a recurrence during 163 and 206 
months of follow-up.    
 
Additional reports with similar findings to those above include the series by Davison et al.,14 
which reported outcomes for 65 patients with LAMN. Five of the 65 patients had AMPD. 
None of the five patients died or had a recurrence during a median 32 months of follow-up 
(1-44 months).  As part of a wider series, Misdraji et al.15 reported outcomes for 10 patients 
with LAMN and AMPD associated with ovarian or fallopian tube involvement. Follow-up was 
available for 7 of the 10 patients; 2 of the 7 died of disease. It was not stated whether the 
ovarian or tubal involvement included cellular deposits or whether the deposits were remote 
from the right lower quadrant. In addition, Carr et al.6 described outcomes for 184 patients 
with appendiceal neoplasms. The outcomes for the 11 patients with AMPD were not detailed 
specifically, but extra-appendiceal epithelial deposits and extra-appendiceal mucin outside 
the right lower quadrant were associated with poorer survival, although it is not possible to 
determine cellularity of these remote MPD based on the description.   
 
Of the 29 patients considered to have only remote AMPD on the basis of initial biopsy, 5 
(17%) were found to have CMPD during definitive surgery. We attribute this finding to the 
fact that MPD can have a heterogeneous distribution, with AMPD at some sites and CMPD 
at other sites, resulting in sampling error on limited diagnostic biopsies. Occult cellularity 
may be present even when a diagnosis of AMPD is made on the basis of adequate 
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sampling.  In cases where the representative sample is of low volume, the potential for 
sampling error should be considered and discussed with the patient when formulating a 
treatment plan. We now perform laparoscopic biopsies in four quadrants of the abdomen 
with the goal of obtaining more representative samples.  If pathologic analyses return a 
report of AMPD, this information along with a consideration of the degree of sampling and 
the CT findings informs the discussion with the patient on the selection of an appropriate 
management plan.    
 
In our study, the presence of visible disease on CT did not correlate with MPD cellularity, but 
the absence of visible disease did: patients who had no visible remote disease on CT were 
much more likely to have AMPD than CMPD. Of the five patients who were upgraded to 
CMPD after CRS, only one had no visible disease on CT. Absence of MPD on imaging 
provides reassurance on the adequacy of sampling, and in our study it was an important 
consideration for treatment recommendations. All of the patients who were observed in the 
current study had no evidence of MPD on initial CT.   
 
The potential limitations of our study include the limited follow-up, the small sample size, 
selection bias, and referral bias. Due to the small number of patients, we chose not to stratify 
this heterogeneous population by disease burden on presentation, which may have 
confounded initial management choices and subsequent outcomes. We also could not 
stratify the patients who underwent CRS according to the level of completeness of 
cytoreduction. However, since patients with rare cancers are likely to seek expert care at a 
comprehensive cancer center, our relatively small sample may in fact be representative of 
the disease at large.   
 
CONCLUSIONS 
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Our results support the recent change to the AJCC classification of MPD (M1a vs M1b) and 
suggest that observation is a viable option for selected patients with AMPD identified on 
initial diagnosis, particularly when the sampling or biopsy is deemed to be representative 
and there are normal findings on imaging. The risk of disease progression and mortality in 
LAMN patients with AMPD appears to be very low. In patients managed by close 
observation in our study, recurrence tended to be a late phenomenon, and based on 
previous reports, such recurrence appears to be salvageable. Imaging every 12 months is 
our preference, given the low rates of recurrence and progression.16    
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FIGURE 1.  Histological appearance of cellular (A) and acellular (B) MPD.  
 
 
 
FIGURE 2. Initial treatment recommendations. 
 
FIGURE 3. Progression of disease (POD) in relation to MPD cellularity. Log-rank P < 
0.001. 
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TABLE 1.  Patient and Treatment Characteristics (n = 48) 
Characteristic No. of Patients (%) 
Age (y)  
   <55 
   55-75 
   >75 
29 (60) 
18 (38) 
1 (2) 
  
Sex  
   Female 
   Male 
31 (64) 
17 (36) 
  
Year of initial assessment     
   1990–1999 
   2000–2009 
   2010–2015 
 9 (19) 
17 (35) 
22 (46) 
  
Index diagnostic procedure  
   Biopsy 
   Appendectomy ± salpingo-oophorectomy 
   Segmental colectomy or CRS  
 
 6 (13) 
25 (52) 
17 (35) 
  
Remote MPD on initial sampling         
   CMPD 
   AMPD 
 
19 (40) 
29 (60) 
  
Visible disease on baseline CT     
   No 
   Yes 
 
15 (31) 
33 (69) 
  
CRS at any point        
   No 
   Yes 
                                                   
 
4 (9) 
 44 (91)* 
 
Initial recommendation at MSK    
   Observe 
   CRS within 6 months 
 
 8 (17) 
40 (83) 
  
Progression of disease after initial management plan 
   No 
   Yes 
 
37 (77) 
11 (23) 
  
Alive   40 (83)†  
*Thirty-eight of the 44 CRS patients underwent the surgery at MSK. No patient 
who underwent a CRS elsewhere either prior to or after the initial assessment 
had a repeat CRS at MSK. 
†Median follow-up, 4 years. Of the eight deaths, six (13% of total patients) were from disease. 
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TABLE 2. Disease and Treatment Characteristics in relation to Mucin Cellularity (n = 48)  
 
Characteristic 
No. of Patients (%) 
P 
CMPD (n = 19)  AMPD (n = 29)  
Index diagnostic procedure   
   Biopsy 
   Appendectomy ± salpingo-oophorectomy 
   Segmental colectomy or CRS  
 
 3 (16) 
 5 (26) 
11 (58) 
 
 3 (10) 
20 (69) 
  6 (21) 
 
 
 
  0.1 
          
MPD on baseline CT  
 
18 (94) 
 
16 (55) 
 
  0.004 
 
MSK recommendation for CRS within 6 mo. 
 
15 (79) 
 
25 (86) 
 
  0.5 
                                                
CRS at any point     
 
18 (94) 
 
26 (90) 
 
  0.5 
                
Remote CMPD on CRS*                      
 
17 (94) 
 
5 (22) 
 
<0.001 
                                 
Complete CRS at MSK (n = 33)†   
 
9 (75) 
 
21 (100) 
 
  0.18 
                                                   
Progression of disease   
 
10 (53)  
 
1 (3)  
 
<0.001 
    
Alive 
 
Deaths 
   From other causes 
   From disease 
12 (63) 
 
7 (37) 
           1 (5) 
6 (32)  
28 (97) 
 
1 (3) 
1 (3) 
         0  
 
 
 
 
0.018  
*Data were available for 41 of 44 patients who underwent CRS. 
†CRS was not performed for 5 of the 38 patients for whom it had been planned at MSK: 2 of the 5 had 
no residual disease at laparoscopy and 3 had extensive disease.  
 
 
